cosibelimab

FDA Drug Profile — UNLOXCYT

Drug Details

Generic Name
cosibelimab
Brand Names
UNLOXCYT
Application Number
BLA761297
Sponsor
Sun Pharmaceutical Industries, Inc.
NDC Codes
3
Dosage Forms
INJECTION, SOLUTION, LIQUID, INJECTION
Routes
INTRAVENOUS
Active Ingredients
COSIBELIMAB, COSIBELIMAB-IPDL

Indications and Usage

1. INDICATIONS AND USAGE UNLOXCYT is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. UNLOXCYT is a programmed death ligand-1 (PD-L1) blocking antibody indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.